AbbVie sales blow past forecasts, fueled by Humira

Oct 31 (Reuters) - AbbVie, which earlier this month walked away from its $55 billion deal to buy Dublin drugmaker Shire, reported quarterly revenue well above Wall Street expectations, fueled by soaring sales of its Humira arthritis drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.